Stay updated on RC48-ADC in Low HER2 Breast Cancer Clinical Trial
Sign up to get notified when there's something new on the RC48-ADC in Low HER2 Breast Cancer Clinical Trial page.

Latest updates to the RC48-ADC in Low HER2 Breast Cancer Clinical Trial page
- Check3 days agoChange DetectedRevision label updated from v3.3.3 to v3.3.4. No substantive study information appears to be modified.SummaryDifference0.0%

- Check10 days agoNo Change Detected
- Check17 days agoChange DetectedThe page now includes an administrative update showing the last known status with sponsor RemeGen Co., Ltd.; date 2023-12; verification status 'Verified'; and 'Unknown status'. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.3%

- Check24 days agoNo Change Detected
- Check32 days agoChange DetectedAdded Beijing Municipality as a study location under Locations. Removed the HHS Vulnerability Disclosure and the Beijing Municipality Locations entry; page revision updated to v3.3.3.SummaryDifference0.2%

- Check53 days agoChange DetectedSite revision updated from v3.2.0 to v3.3.2. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check60 days agoChange DetectedThe funding notice near the top of the page has been removed, eliminating the disclosure about potential delays in updates due to funding gaps. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.3%

- Check82 days agoChange DetectedNo additions or deletions were detected in the Study Details page. The content appears consistent with the previous version, including the study design, eligibility criteria, outcomes, and contact information.SummaryDifference0.3%

Stay in the know with updates to RC48-ADC in Low HER2 Breast Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the RC48-ADC in Low HER2 Breast Cancer Clinical Trial page.